Serum 7α-C4 as a Diagnostic Biomarker for Bile Acid Malabsorption
Serum 7α-C4 (7α-hydroxy-4-cholesten-3-one) is a useful and recommended biomarker for diagnosing bile acid malabsorption in patients with chronic diarrhea, including IBS-D and functional diarrhea, though the evidence quality is very low. 1
Guideline Recommendations
The Canadian Association of Gastroenterology (2020) conditionally recommends using serum C4 assay to identify possible bile acid malabsorption in patients with chronic diarrhea, including IBS-D and functional diarrhea 1. This recommendation is based on very-low-certainty evidence, with 80% of the consensus panel voting "yes" or "strongly yes."
The American Gastroenterological Association (2019) suggests testing for bile acid diarrhea in patients with chronic diarrhea, though they note that serum 7α-C4 was not yet commercially available at the time of their guideline publication 2. They recommend an empiric trial of bile acid binders when commercial assays are unavailable.
Diagnostic Performance
Cutoff Values and Accuracy
The most robust research data support the following diagnostic thresholds:
Cutoff of 48.3-52.5 ng/mL demonstrates optimal diagnostic accuracy:
When using 48.3 ng/mL cutoff in patients with diarrhea, 7α-C4 identifies those with low FGF19 (<60 pg/mL) with 91% sensitivity and 95.5% specificity 4
52% of patients with elevated 7α-C4 (>48.9 ng/mL) also had low FGF19, compared to only 8% below this threshold 3
Normal Reference Range
The established normal range is 6-48 ng/mL (5th to 95th percentile) based on 106-111 healthy controls 5, 6. Some studies use cutoffs of 28-30 ng/mL for initial screening, though higher thresholds (48-52.5 ng/mL) provide better specificity 7.
Clinical Context and Performance
Where 7α-C4 Performs Best
Ileal disease and resection: Patients with Crohn's disease and ileal resection show markedly elevated levels (median 51.6-100 ng/mL depending on presence of ileitis), compared to ulcerative colitis (median 11.8 ng/mL) 4. This represents the strongest clinical signal.
Post-cholecystectomy diarrhea: 7α-C4 elevation is more frequent in patients with prior cholecystectomy (22.7%) versus those without (3.8%) 8.
IBS-D: Significantly higher mean values compared to healthy controls, though the elevation is less dramatic than in structural ileal disease 5.
Correlation with Other Markers
- Strong inverse correlation with FGF19 (r = -0.64 to -0.72, P<0.001) 3, 4, 7
- Positive correlation with daily bowel movements (r = 0.41-0.71, P<0.004) 3, 4
- Good inverse correlation with SeHCAT retention (the European gold standard), though SeHCAT itself has very-low-certainty evidence 1
Important Limitations and Caveats
Evidence Quality Issues
The Canadian guideline downgraded evidence to very low due to:
- Moderately serious risk of bias
- Very serious imprecision (small sample sizes, confidence intervals crossing clinical utility thresholds)
- SeHCAT (used as reference standard in many studies) is itself not adequately validated 1
Diagnostic Performance Concerns
When compared to 48-hour fecal bile acid measurement (the true physiologic reference standard), 7α-C4 showed:
- Only 40% sensitivity and 85% specificity
- 40% positive predictive value
- 85% negative predictive value 1
This is substantially lower than the 82-91% sensitivity reported in studies using SeHCAT or FGF19 as reference standards.
Pre-analytical Considerations
Sample stability: 7α-C4 declines by up to 14% after 72 hours in unseparated blood, though changes are <5% at 12 hours 9. Collect fasting samples and separate within 12 hours to ensure accuracy.
Active inflammation: Patients with active ulcerative colitis have diarrhea but normal 7α-C4 levels, indicating the test specifically identifies bile acid-mediated diarrhea, not inflammatory diarrhea 4.
Practical Clinical Algorithm
Order fasting serum 7α-C4 in patients with chronic diarrhea (>3 liquid bowel movements/day) after excluding active inflammation, infection, and celiac disease
Interpret results:
- <48 ng/mL: Bile acid malabsorption unlikely; consider other causes
- 48-60 ng/mL: Borderline; consider empiric trial of bile acid sequestrants
- >60 ng/mL: Bile acid malabsorption highly likely; initiate bile acid sequestrant therapy
Highest yield populations:
- Crohn's disease with ileal involvement or resection
- Post-cholecystectomy chronic diarrhea
- IBS-D refractory to standard therapy
- Functional diarrhea
If 7α-C4 unavailable: Empiric trial of bile acid sequestrants (cholestyramine, colesevelam) is reasonable given the low risk and potential benefit 1, 2
Cost Considerations
7α-C4 testing costs approximately $420 USD and can be performed domestically in many countries, representing a 49% cost savings compared to combined fecal bile acid testing ($825 USD including international shipping) 8. The test correlates well with total bile acids and can be elevated despite normal fecal bile acid levels, making it a cost-effective first-line screening tool.